Related references
Note: Only part of the references are listed.Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
L. Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
interleukin-2: Biology, Design and Application
Natalia Arenas-Ramirez et al.
TRENDS IN IMMUNOLOGY (2015)
In Vivo Maintenance of Human Regulatory T Cells during CD25 Blockade
David J. Huss et al.
JOURNAL OF IMMUNOLOGY (2015)
CD56bright natural killer cells and response to daclizumab HYP in relapsing-remitting MS
J. Elkins et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
Wei Liao et al.
IMMUNITY (2013)
IL-2-dependent adaptive control of NK cell homeostasis
Georg Gasteiger et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells
Georg Gasteiger et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
IL-2 coordinates IL-2-producing and regulatory T cell interplay
Ines F. Amado et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
Ralf Gold et al.
LANCET (2013)
CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients
Andrew J. Rech et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages
Wei Liao et al.
NATURE IMMUNOLOGY (2011)
In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcγRIII+ phagocytes
Yulius Y. Setiady et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity
Thomas R. Malek et al.
IMMUNITY (2010)
An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2-Driven Activation of CD56bright NK Cells
Jayne F. Martin et al.
JOURNAL OF IMMUNOLOGY (2010)
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. (vol 9, pg 381, 2010)
D. Wynn et al.
LANCET NEUROLOGY (2010)
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
Daniel Wynn et al.
LANCET NEUROLOGY (2010)
Recent Advances in the Genetics of Autoimmune Disease
Peter K. Gregersen et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis
Bibiana Bielekova et al.
ARCHIVES OF NEUROLOGY (2009)
How Punctual Ablation of Regulatory T Cells Unleashes an Autoimmune Lesion within the Pancreatic Islets
Markus Feuerer et al.
IMMUNITY (2009)
Anti-CD25 Antibody-Mediated Depletion of Effector T Cell Populations Enhances Susceptibility of Mice to Acute but Not Chronic Toxoplasma gondii Infection
Kevin N. Couper et al.
JOURNAL OF IMMUNOLOGY (2009)
Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation
Min Shi et al.
IMMUNITY (2008)
Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor α-chain expression
Wei Liao et al.
NATURE IMMUNOLOGY (2008)
Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1
Masahiro Ono et al.
NATURE (2007)
Incomplete depletion and rapid regeneration of Foxp3+ regulatory T cells following anti-CD25 treatment in malaria-infected mice
Kevin N. Couper et al.
JOURNAL OF IMMUNOLOGY (2007)
Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation
Arian Laurence et al.
IMMUNITY (2007)
Regulatory T cells dynamically control the primary immune response to foreign antigen
Dipica Haribhai et al.
JOURNAL OF IMMUNOLOGY (2007)
Comment on cutting edge:: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells
Leigh A. Stephens et al.
JOURNAL OF IMMUNOLOGY (2006)
FOXP3 controls regulatory T cell function through cooperation with NFAT
Yongqing Wu et al.
CELL (2006)
Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis
B Bielekova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Cutting edge:: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+ CD25+ T regulatory cells
Adam P. Kohm et al.
JOURNAL OF IMMUNOLOGY (2006)
A function for interleukin 2 in Foxp3-expressing regulatory T cells
JD Fontenot et al.
NATURE IMMUNOLOGY (2005)
FcγRIV:: A novel FcR with distinct IgG subclass specificity
F Nimmerjahn et al.
IMMUNITY (2005)
Homeostatic maintenance of natural Foxp3+ CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization
R Setoguchi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Regulatory T cell lineage specification by the forkhead transcription factor FoxP3
JD Fontenot et al.
IMMUNITY (2005)
Interleukin 2 plays a central role in Th2 differentiation
J Cote-Sierra et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis
E Bettelli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Interleukin 2 signaling is required for CD4+ regulatory T cell function
GC Furtado et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice:: implications for the nonredundant function of IL-2
TR Malek et al.
IMMUNITY (2002)
Cutting edge:: Depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease
RS McHugh et al.
JOURNAL OF IMMUNOLOGY (2002)
Share Paper
